

IN THE CLAIMS:

Please amend the claims as follows:

- 1-37. (Canceled)
- 38. (Previously presented): A method for significantly reducing a risk of cardiovascular disease in a post-menopausal female human subject, the method comprising administering an effective dose of an ACE inhibitor to the post-menopausal female human subject, whereby the risk of cardiovascular disease in the post-menopausal female human subject is significantly reduced.
- 39. (Canceled)
- 40. (New): The method of claim 38, wherein the ACE inhibitor comprises ramipril.
- 41. (New): The method of claim 38, wherein the post-menopausal female human subject comprises a subject free of hypertension, congestive heart failure, left ventricular dysfunction, prior myocardial infarct, and induced activation of the renin-angiotensin system.
- 42. (New): The method of claim 38, wherein reducing the risk of cardiovascular disease in the post-menopausal female human subject comprises significantly reducing a plasma level of PAI-1 in the post-menopausal female human subject.
- 43. (New): The method of claim 42, wherein significantly reducing the plasma level of PAI-1 comprises reducing the plasma level of PAI-1 by at least about 35% compared to a baseline plasma level of PAI-1.

Serial No.: 09/974,703

44. (New): The method of claim 43, wherein the post-menopausal female human subject comprises a subject comprising a PAI-1 polymorphism, wherein the PAI-1 polymorphism is correlated with elevated levels of PAI-1 activity.
45. (New): The method of claim 44, wherein the PAI-1 polymorphism comprises a 4G PAI-1 polymorphism.